With the healthcare and life sciences sector at the heart of the pandemic, we are seeing some new issues arising in the already complex world of life sciences collaborations, for both coronavirus-related and other products and therapies.

The Life Sciences Collaborations: Key Considerations in the COVID-19 Era document is a high-level guide that outlines a list of issues that to consider in executing these types of agreements in the COVID-19 era. This includes areas such as: governance, development and regulatory activities, manufacture and supply, commercialization, diligence, licenses and exclusivity, financial provisions, IP, representations, warranties and indemnifications, dispute resolution and risk management, and antitrust.

Our team of over 800 attorneys dedicated to the healthcare and life sciences industry across 46 countries in the transactional, regulatory, antitrust, intellectual property and data compliance practice groups is experienced in addressing the issues impacting the research, development, manufacturing and commercialization of your products.

Please click on the button below to request for access or contact your Baker McKenzie lawyer.

 

Previous articleGlobal: ESG Webinar Series
Next articleGlobal: Export Credit Agency Export Finance